Last edition
News about "LQTS2"
Thryv Therapeutics Initiates Wave II Phase II/III Trial for Long QT Syndrome Type 2
Thryv Therapeutics has launched the Wave II Phase II/III trial to evaluate THRV-1268, an oral SGK1 inhibitor, as a potential disease-modifying therapy for adults with Long QT Syndrome Type 2.
LQTS2 | 14/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members